Phenomena and pathological significances of the methylated p16 promotor in DNA derived from plasma and blood cells of patients with systemic lupus erythematosus

An Sheng Li, Yu Mei Li, Ai Zhen Yang, Xu Yao, Zhi Qiang Chen

Research output: Contribution to journalArticle

Abstract

Objective: To detect the methylation status of p16 gene promotor in DNA derived from plasma and blood cells of patients with systemic lupus erythematosus (SLE), and it's relationship with clinical symptoms. Methods: p16 promotor methylation in plasma and peripheral blood cells (PBCs) DNA were simultaneously detected with the methylation specific PCR (MSP) method in 24 active SLE patients, 21 inactive SLE patients, as well as 20 healthy controls. Results: In the plasma DNA, p16 gene methylation ratio (MP%) was higher in SLE patients than in the healthy controls (64.4% vs. 5.0%, P <0.05). MP% in the active SLE patients was significantly higher than that in the inactive SLE patients (83.3% vs. 42.9%, P <0.05). In the PBCs, p16 gene methylation ratio (MC%) in the healthy controls was significantly higher than that in SLE (80.0% vs. 48.9%, P <0.05). MC% in the active SLE patients (29.2%) was the lowest among three groups. There was no significant difference between the inactive SLE patients and healthy controls (71.4% vs. 80.0%, P > 0.05). Each patient could be judged as one of the four methylation patterns: MP/MC, UP/MC (UP: unmethylated plasma p16), MP/UC (UC: unmethylated PBCs p16), and UP/UC. The ratios of MP/MC and UP/UC were similar between the active and inactive SLE patients. However, different distributions of other two patterns were found in the active and inactive SLE patients as UP/MC 4.2% vs. 42.9% (P <0.05) and MP/UC 58.3% vs. 14.3% (P <0.05), respectively. The active SLE patients with MP/UC and the inactive SLE patients with UP/MC showed different clinical symptoms and laboratory examinations. Significant correlation was found between the disease activity index for lupus patients (SLEDAI) scores and MP% (r = 0.93), between the SLEDAI scores and MC% (r = -0.96) also between MC% and MP% (r = -0.79). Conclusion: The p16 methylation assay provides available information for the diagnosis, judgment of disease activity, as well as novel insights into the pathogenesis underlying this disease.

Original languageEnglish (US)
Pages (from-to)675-681
Number of pages7
JournalZhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae.
Volume28
Issue number5
StatePublished - Oct 2006
Externally publishedYes

Fingerprint

Plasma Cells
Systemic Lupus Erythematosus
Blood Cells
DNA
Methylation
p16 Genes
Polymerase Chain Reaction

Keywords

  • Methylation
  • p16 gene
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Phenomena and pathological significances of the methylated p16 promotor in DNA derived from plasma and blood cells of patients with systemic lupus erythematosus. / Li, An Sheng; Li, Yu Mei; Yang, Ai Zhen; Yao, Xu; Chen, Zhi Qiang.

In: Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae., Vol. 28, No. 5, 10.2006, p. 675-681.

Research output: Contribution to journalArticle

@article{832f96c553bb44a6ac960eeb06d1307b,
title = "Phenomena and pathological significances of the methylated p16 promotor in DNA derived from plasma and blood cells of patients with systemic lupus erythematosus",
abstract = "Objective: To detect the methylation status of p16 gene promotor in DNA derived from plasma and blood cells of patients with systemic lupus erythematosus (SLE), and it's relationship with clinical symptoms. Methods: p16 promotor methylation in plasma and peripheral blood cells (PBCs) DNA were simultaneously detected with the methylation specific PCR (MSP) method in 24 active SLE patients, 21 inactive SLE patients, as well as 20 healthy controls. Results: In the plasma DNA, p16 gene methylation ratio (MP{\%}) was higher in SLE patients than in the healthy controls (64.4{\%} vs. 5.0{\%}, P <0.05). MP{\%} in the active SLE patients was significantly higher than that in the inactive SLE patients (83.3{\%} vs. 42.9{\%}, P <0.05). In the PBCs, p16 gene methylation ratio (MC{\%}) in the healthy controls was significantly higher than that in SLE (80.0{\%} vs. 48.9{\%}, P <0.05). MC{\%} in the active SLE patients (29.2{\%}) was the lowest among three groups. There was no significant difference between the inactive SLE patients and healthy controls (71.4{\%} vs. 80.0{\%}, P > 0.05). Each patient could be judged as one of the four methylation patterns: MP/MC, UP/MC (UP: unmethylated plasma p16), MP/UC (UC: unmethylated PBCs p16), and UP/UC. The ratios of MP/MC and UP/UC were similar between the active and inactive SLE patients. However, different distributions of other two patterns were found in the active and inactive SLE patients as UP/MC 4.2{\%} vs. 42.9{\%} (P <0.05) and MP/UC 58.3{\%} vs. 14.3{\%} (P <0.05), respectively. The active SLE patients with MP/UC and the inactive SLE patients with UP/MC showed different clinical symptoms and laboratory examinations. Significant correlation was found between the disease activity index for lupus patients (SLEDAI) scores and MP{\%} (r = 0.93), between the SLEDAI scores and MC{\%} (r = -0.96) also between MC{\%} and MP{\%} (r = -0.79). Conclusion: The p16 methylation assay provides available information for the diagnosis, judgment of disease activity, as well as novel insights into the pathogenesis underlying this disease.",
keywords = "Methylation, p16 gene, Systemic lupus erythematosus",
author = "Li, {An Sheng} and Li, {Yu Mei} and Yang, {Ai Zhen} and Xu Yao and Chen, {Zhi Qiang}",
year = "2006",
month = "10",
language = "English (US)",
volume = "28",
pages = "675--681",
journal = "Acta Academiae Medicinae Sinicae",
issn = "1000-503X",
publisher = "Chinese Academy of Medical Sciences",
number = "5",

}

TY - JOUR

T1 - Phenomena and pathological significances of the methylated p16 promotor in DNA derived from plasma and blood cells of patients with systemic lupus erythematosus

AU - Li, An Sheng

AU - Li, Yu Mei

AU - Yang, Ai Zhen

AU - Yao, Xu

AU - Chen, Zhi Qiang

PY - 2006/10

Y1 - 2006/10

N2 - Objective: To detect the methylation status of p16 gene promotor in DNA derived from plasma and blood cells of patients with systemic lupus erythematosus (SLE), and it's relationship with clinical symptoms. Methods: p16 promotor methylation in plasma and peripheral blood cells (PBCs) DNA were simultaneously detected with the methylation specific PCR (MSP) method in 24 active SLE patients, 21 inactive SLE patients, as well as 20 healthy controls. Results: In the plasma DNA, p16 gene methylation ratio (MP%) was higher in SLE patients than in the healthy controls (64.4% vs. 5.0%, P <0.05). MP% in the active SLE patients was significantly higher than that in the inactive SLE patients (83.3% vs. 42.9%, P <0.05). In the PBCs, p16 gene methylation ratio (MC%) in the healthy controls was significantly higher than that in SLE (80.0% vs. 48.9%, P <0.05). MC% in the active SLE patients (29.2%) was the lowest among three groups. There was no significant difference between the inactive SLE patients and healthy controls (71.4% vs. 80.0%, P > 0.05). Each patient could be judged as one of the four methylation patterns: MP/MC, UP/MC (UP: unmethylated plasma p16), MP/UC (UC: unmethylated PBCs p16), and UP/UC. The ratios of MP/MC and UP/UC were similar between the active and inactive SLE patients. However, different distributions of other two patterns were found in the active and inactive SLE patients as UP/MC 4.2% vs. 42.9% (P <0.05) and MP/UC 58.3% vs. 14.3% (P <0.05), respectively. The active SLE patients with MP/UC and the inactive SLE patients with UP/MC showed different clinical symptoms and laboratory examinations. Significant correlation was found between the disease activity index for lupus patients (SLEDAI) scores and MP% (r = 0.93), between the SLEDAI scores and MC% (r = -0.96) also between MC% and MP% (r = -0.79). Conclusion: The p16 methylation assay provides available information for the diagnosis, judgment of disease activity, as well as novel insights into the pathogenesis underlying this disease.

AB - Objective: To detect the methylation status of p16 gene promotor in DNA derived from plasma and blood cells of patients with systemic lupus erythematosus (SLE), and it's relationship with clinical symptoms. Methods: p16 promotor methylation in plasma and peripheral blood cells (PBCs) DNA were simultaneously detected with the methylation specific PCR (MSP) method in 24 active SLE patients, 21 inactive SLE patients, as well as 20 healthy controls. Results: In the plasma DNA, p16 gene methylation ratio (MP%) was higher in SLE patients than in the healthy controls (64.4% vs. 5.0%, P <0.05). MP% in the active SLE patients was significantly higher than that in the inactive SLE patients (83.3% vs. 42.9%, P <0.05). In the PBCs, p16 gene methylation ratio (MC%) in the healthy controls was significantly higher than that in SLE (80.0% vs. 48.9%, P <0.05). MC% in the active SLE patients (29.2%) was the lowest among three groups. There was no significant difference between the inactive SLE patients and healthy controls (71.4% vs. 80.0%, P > 0.05). Each patient could be judged as one of the four methylation patterns: MP/MC, UP/MC (UP: unmethylated plasma p16), MP/UC (UC: unmethylated PBCs p16), and UP/UC. The ratios of MP/MC and UP/UC were similar between the active and inactive SLE patients. However, different distributions of other two patterns were found in the active and inactive SLE patients as UP/MC 4.2% vs. 42.9% (P <0.05) and MP/UC 58.3% vs. 14.3% (P <0.05), respectively. The active SLE patients with MP/UC and the inactive SLE patients with UP/MC showed different clinical symptoms and laboratory examinations. Significant correlation was found between the disease activity index for lupus patients (SLEDAI) scores and MP% (r = 0.93), between the SLEDAI scores and MC% (r = -0.96) also between MC% and MP% (r = -0.79). Conclusion: The p16 methylation assay provides available information for the diagnosis, judgment of disease activity, as well as novel insights into the pathogenesis underlying this disease.

KW - Methylation

KW - p16 gene

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=37849189762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37849189762&partnerID=8YFLogxK

M3 - Article

VL - 28

SP - 675

EP - 681

JO - Acta Academiae Medicinae Sinicae

JF - Acta Academiae Medicinae Sinicae

SN - 1000-503X

IS - 5

ER -